Steroids for COVID-19 treatment

 PATHOPHYSIOLOGY OF AKI IN COVID- 19 PATIENTS. AKI appears to involve a complex process driven by virus-mediated injury, cytokine storm, AngII pathway activation, dysregulation of complement, hypercoagulation, and microangiopathy interacting with common and known risk factors for AKI . There is paucity of data regarding clinical and laboratory characteristics of AKI in patients with COVID-19. We urge that further studies describing and analyzing the clinical course of patients with COVID-19 include appropriate indices of kidney function and diagnosis of AKI in their analyses, including kidney injury markers, urine microscopy, quantified urine protein, urine output, and urine electrolytes. Markers of macrophage activation, coagulation, microangiopathy, and complement activation, as well as kidney imaging and need for KRT (with relevant details), are important data needed to further our understanding of AKI pathophysiology associated with COVID-19. Rates of reversibility of, or partial improvement in, kidney function and any kidney biopsy results (including immunofluorescence and electron microscopy) should be reported. In the rush to report medical complications of COVID-19, we are missing valuable clinical information. Speculation about specific interventions would not be appropriate until we obtain appropriate information. We advocate for a complete and standardized appraisal of the clinical and laboratory picture so that preventative and therapeutic strategies for AKI can be appropriately designed and implemented.

30 year old male, 10 day history of diarrhoea and reduced oral intake, presented with lethargy and ongoing abdominal cramps. No respiratory symptoms, but O2 sats noted to be on the lower side, exertional O2 sats dropped to 86%. No past medical history of note, normal white cell count, not lymphopenic, urea 18.9 mmol/L, creatinine: 489 µmol/L, amylase 600 (30-118), ALT: 65, CRP: 100, Trop I 267 (0-46). Chest X-ray as shown. What do you think the patient is suffered from?

41 year old male presents to the ED with SOB x5 days. He was in contact with a COVID+ patient. He reports fever highest 102.3. States he has body aches and chills. Denies cough or sore throat. Places on 6L/min via NC and sats increased to 91%. History of Hypertension Hypothyroidism Morbid obesity Prediabetes. what do you suggest?

81 years old male, known COPD, presents with high grade fever, cough n SOB for last 6 days. His CRP is normal. D dimer, FERRITIN awaited. Anaemia present otherwise normal hemogram. Chest auscultation revealed bilateral expiratory rhonchi n RT LZ CREPITATIONS. Spo2 95% on air. Normal Temperature, BP n Pulse. His SARS COV 2 RT PCR came positive. Kindly discuss further management plan for this patient.

Pregnant women do not appear more likely to contract the infection than the general population. However, pregnancy itself alters the body’s immune system and response to viral infections in general, which can occasionally be related to more severe symptoms and this will be the same for COVID-19. Transmission  With regard to vertical transmission (transmission from mother to baby antenatally or intrapartum), emerging evidence now suggests that vertical transmission is probable, although the proportion of pregnancies affected and the significance to the neonate has yet to be determined.  At present, there are no recorded cases of vaginal secretions being tested positive for COVID-19.  At present, there are no recorded cases of breast milk being tested positive for COVID-19. Effect on Foetus  There are currently no data suggesting an increased risk of miscarriage or early pregnancy loss in relation to COVID-19.  There is no evidence currently that the virus is teratogenic. Long term data is awaited.  COVID-19 infection is currently not an indication for Medical Termination of Pregnancy. General Guidelines for Obstetric Health Care Providers  Ob-gyns and other health care practitioners should contact their local and/or state health department for guidance on testing persons under investigation and should follow the national protocol.  Health care practitioners should immediately notify infection control personnel at their health care facility and their local or state health department in the event of a PUI for COVID-19.  A registry for all women admitted to with confirmed COVID-19 infection in pregnancy should be maintained. Maternal and neonatal records including outcome should be completed in detail and preserved for analysis in future.  Health care providers should create a plan to address the possibility of a decreased health care workforce, potential shortage of personal protective equipment, limited isolation rooms, and should maximize the use of telehealth across as many aspects of prenatal care as possible.  Each facility should consider their appropriate space and staffing needs to prevent transmission of the virus that causes COVID-19.  Pregnant women should be advised to increase their social distancing to reduce the risk of infection and practice hand hygiene.  Health care practitioners should promptly notify infection control personnel at their facility of the anticipated arrival of a pregnant patient who has confirmed COVID-19 or is a PUI so that infection control measures can be kept in place.  Intrapartum services should be provided in a way that is safe, with reference to minimum staffing requirements and the ability to provide emergency obstetric, anaesthetic and neonatal care where indicated. To read complete guidelines- https://icmr.nic.in/sites/default/files/upload_documents/Guidance_for_Management_of_Pregnant_Women_in_COVID19_Pandemic_12042020.pdf